PMID- 26181549
OWN - NLM
STAT- MEDLINE
DCOM- 20151005
LR  - 20181113
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 94
IP  - 28
DP  - 2015 Jul
TI  - Sitagliptin After Ischemic Stroke in Type 2 Diabetic Patients: A Nationwide 
      Cohort Study.
PG  - e1128
LID - 10.1097/MD.0000000000001128 [doi]
LID - e1128
AB  - The cerebrovascular safety and efficacy of sitagliptin, a dipeptidyl peptidase-4 
      inhibitor, in patients with type 2 diabetes mellitus (T2DM) with ischemic stroke 
      remains uncertain. The aim of this study was to assess the efficacy and safety of 
      sitagliptin in patients with T2DM with recent ischemic stroke. We analyzed data 
      from the Taiwan National Health Insurance Research Database between March 1, 
      2009, and December 31, 2011. Ischemic stroke patients were identified from 
      individuals with T2DM. Patients who received sitagliptin were compared with those 
      who did not to evaluate the cardiovascular safety and efficacy of sitagliptin. 
      The primary outcome was a composite of ischemic stroke, myocardial infarction, or 
      cardiovascular death. A total of 5145 type 2 diabetic patients with ischemic 
      stroke met our inclusion criteria and were followed for up to 2.83 years (mean, 
      1.17 years). Overall, 1715 patients (33.3%) received sitagliptin and 3430 
      patients (66.7%) did not. The primary composite outcome occurred in 190 patients 
      in the sitagliptin group (11.1%) and in 370 patients in the comparison group 
      (10.8%) (hazard ratio [HR] = 1.02; 95% confidence interval [CI], 0.85-1.21). 
      Patients treated with sitagliptin had a similar risk of ischemic stroke, 
      hemorrhagic stroke, and all-cause mortality with an HR of 0.95 (95% CI, 
      0.78-1.16, P = 0.612), 1.07 (95% CI, 0.55-2.11, P = 0.834), and 1.00 (95% CI, 
      0.82-1.22, P = 0.989), respectively, compared with patients not treated with 
      sitagliptin. Treatment with sitagliptin in type 2 diabetic patients with recent 
      ischemic stroke was not associated with increased or decreased risks of adverse 
      cerebrovascular outcomes.
FAU - Chen, Dong-Yi
AU  - Chen DY
AD  - From the Division of Cardiology (DYC, MLT, CCC, MSW, CCW, ICH, KCH), Department 
      of Internal Medicine; Department of Medical Education (SHW), Chang Gung Memorial 
      Hospital, Chang Gung University College of Medicine; Division of Cardiology (CTM, 
      WJC, THC), Department of Internal Medicine, Chang Gung Memorial Hospital, 
      Keelung, and Chang Gung University College of Medicine, Taoyuan; Division of 
      Cardiology (YSL), Department of Internal Medicine, Chang Gung Memorial Hospital, 
      Chiayi, and Chang Gung University College of Medicine, Taoyuan; and Department of 
      Neurology (FCS), Chang Gung Memorial Hospital, Keelung, Taiwan.
FAU - Wang, Szu-Heng
AU  - Wang SH
FAU - Mao, Chun-Tai
AU  - Mao CT
FAU - Tsai, Ming-Lung
AU  - Tsai ML
FAU - Lin, Yu-Sheng
AU  - Lin YS
FAU - Su, Feng-Chieh
AU  - Su FC
FAU - Chou, Chung-Chuan
AU  - Chou CC
FAU - Wen, Ming-Shien
AU  - Wen MS
FAU - Wang, Chun-Chieh
AU  - Wang CC
FAU - Hsieh, I-Chang
AU  - Hsieh IC
FAU - Hung, Kuo-Chun
AU  - Hung KC
FAU - Cherng, Wen-Jin
AU  - Cherng WJ
FAU - Chen, Tien-Hsing
AU  - Chen TH
LA  - eng
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Pyrazines)
RN  - 0 (Triazoles)
RN  - TS63EW8X6F (Sitagliptin Phosphate)
SB  - IM
MH  - Aged
MH  - Cohort Studies
MH  - Diabetes Mellitus, Type 2/*complications/*drug therapy
MH  - Dipeptidyl-Peptidase IV Inhibitors/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pyrazines/*therapeutic use
MH  - Sitagliptin Phosphate
MH  - Stroke/chemically induced/*prevention & control
MH  - Treatment Outcome
MH  - Triazoles/*therapeutic use
PMC - PMC4617065
COIS- The authors have conflicts of interest to disclose.
EDAT- 2015/07/17 06:00
MHDA- 2015/10/06 06:00
PMCR- 2015/07/17
CRDT- 2015/07/17 06:00
PHST- 2015/07/17 06:00 [entrez]
PHST- 2015/07/17 06:00 [pubmed]
PHST- 2015/10/06 06:00 [medline]
PHST- 2015/07/17 00:00 [pmc-release]
AID - 00005792-201507030-00018 [pii]
AID - 10.1097/MD.0000000000001128 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2015 Jul;94(28):e1128. doi: 10.1097/MD.0000000000001128.